Menu visibility control

Video

Events

Startup Surgery

Most Recent

Investments

On-demand delivery firm Quiqup gets £20m as it gears up for global expansion

News

Ex-CEO of Ve Interactive under investigation for fraud

Investments

EXCLUSIVE: E-commerce firm Paddle merges with DevMate in ‘seven figure’ deal

Press Releases

Zzish hits £1.15m funding target on Crowdcube for technology that will democratise quality education and move the needle on learning
Okappy announces the launch of its investment pitch on the AngelsDen equity crowdfunding platform
Recruitment disruptor talent.io poised for further growth with €8m investment secured

London-based biotech company Pulmocide raises $30.4m Series B

biotech
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Pulmocide, a biotech firm run by former GlaxoSmithKline scientists, has closed a $30.4m Series B.

The funding, which will be used to further develop its wholly-owned treatments for respiratory syncytial virus (RSV) and pulmonary aspergillosis, came from SV Life Sciences, Johnson & Johnson’s venture capital arm.

The London-based company also drew support from Touchstone Innovations and F-prime, the venture capital arm of Fidelity.

A $40m funding round, Snapchat’s poor results, Deliveroo’s first acquisition and more in The Week in Tech

“Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need,” said company CEO Garth Rapeport.

“Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis. Our approach is to direct the drug to the site of the infection through an inhaler,” he explained.

The funding, the CEO added, will enable the firm to advance two of its ‘novel’ compounds through early clinical development.

“We are delighted by the interest we’ve received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide. We look forward to providing further pipeline updates as developments progress with our important programmes,” Rapeport added.

The news comes after the biotech firm secured $17m Series A round from four investors in November 2013.

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

Quiqup team photo

On-demand delivery firm Quiqup gets £20m as it gears up for global expansion
posted 10 hours ago

David Brown, VE

Ex-CEO of Ve Interactive under investigation for fraud
posted 18 hours ago

paddle team

EXCLUSIVE: E-commerce firm Paddle merges with DevMate in ‘seven figure’ deal
posted 19 hours ago

CalumSmeaton

Calum Smeaton, CEO of TVSquared, on growing a successful UK AdTech firm and raising $12.5m
posted 22 hours ago

diversity uk vc

Research spotlights lack of women in UK venture capital industry
posted 24 hours ago

Labour’s Manifesto: what does it mean for UK tech?
posted on May 23, 2017